Erin, this is a very good question. Yes. We continue to believe that the COVID-19 testing is quite durable, right? We've already gotten massive returns on those investments. The COVID-19 pandemic has continued to challenge both our health and our way of life this year. We'll continue to do our part at Fulgent to help to get testing solutions to individuals and organizations that need them so that business, school, sporting events, travel, and social engagements can resume safely. COGS per test for the quarter was $25, an improvement of approximately 42% compared to the second quarter. As Ming mentioned, we delivered more than 1 million reports during the third quarter, an almost fiftyfold increase year over year, and an almost fivefold increase sequentially. I will review the highlights from our third quarter, before I hand it over to our chief commercial officer, Brandon Perthuis, to provide updates on our commercial success and the go-to-market strategy. “Miami-Dade residents now have improved access to reliable and fast COVID-19 testing. More so than ever, we are working closely with the payers and are making progress becoming an in-network provider. Overall, I'm very pleased with the execution of our sales team in the quarter as we consistently won in competitive opportunities. So we are on track with our original guidance, which is quite a feat, because a lot of the diagnostics companies, 2020 was essentially a throwaway year. We were able to launch this high capacity lab in record time by building on top of our foundational Fulgent technology. We don't have that crystal ball, no one does, right? Customers are using Fulgent for hereditary cancer, cardiovascular genetics, neurological genetics, reproductive health, and other newer tests that we've launched in the last 12 to 18 months. Fulgent Genetics, Miami-Dade County Partner on COVID-19 testing Miami-Dade switches to the Fulgent RT-PCR test and Community Testing Platform TEMPLE CITY, Calif., Sept. 09, … Customers are using Fulgent for hereditary cancer, cardiovascular genetics, neurological genetics, reproductive health, and other newer tests that we've launched in the last 12 to 18 months. And, Rachel, Brandon. So we definitely could program or repurpose some of those equipment, getting into the mix of our complete automation for the lab automation. Displayed here are Job Ads that match your query. This system also includes heat maps and contact tracing functionality. Fulgent Genetics is followed by the analysts listed above. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Simply put, it's the best test. So COVID is not going to go away at the end of 2020. Great. Our investment in terms of capacity, it is always the multiple-use. And yes, in terms of meeting the turnaround time to get that extra reimbursement, we are incredibly confident in our ability to do that. And actually, I got a text that I cut out a little bit. In the meantime, we continue to add contents and add additional tests for our core business to address the growing need for the genetic testing market. Page 1 of 24 jobs. I'd like to spend a few minutes to discuss each of these in detail. This rate releases our valuation allowance on our deferred-tax assets and incorporates our projected annual tax rate for the year. Ladies and gentlemen, thank you for standing by, and welcome to the Q3 2020 Fulgent Genetics earnings conference call. Great. Combining next generation sequencing (“NGS”) with its technology platform, the Company performs full-gene sequencing with deletion/duplication analysis in an array of panels that can be tailored to meet specific customer needs. So we hope that will stick around. We believe the process is similar to buying coffee with a QR code on your cell phone; cars drive up, show their phone, scan the kit, self-administer the shallow nasal swab and drive off. I think as Paul mentioned, we do have some additional leverage in our COGS there. So you can break out the investments that we made, as well as the spending in a couple of different buckets. “Miami-Dade residents now have improved access to … We've continued to bring on new customers. The increase is attributable to the vast majority of our tests now going through reimbursement and our favorable payment experienced today. This has been in large part due to our ability to win new clients while maintaining relationships with existing clients, even as some of those clients experienced lower test volumes amid the pandemic. Gross margin improved almost 19% points sequentially. The Blueshirt Group Fulgent Genetics, Inc. is a technology company. But we think we're extremely well-positioned to be a major player in this market. With a modest level of investment in the infrastructure and headcount, we were able to grow our test volume almost 50 times or 5,000% of that in the third quarter of last year and by more than 5 times or 500% of that in the second quarter of this year. Non-GAAP operating expenses totaled $9.2 million, up from six [Audio gap] quarter. To that end, we believe the investment we made to build our COVID-19 test initiatives will continue to benefit our business in long term. I want to visit genetic testing, and Paul, some of your comments with regard to how to think about that portion of the business for the year. So I'll reemphasize what I said. In the future, we plan to add additional pathogens to our panel to provide comprehensive testing for patients with respiratory infections. Our original offering consists of three tests: carrier screening, newborn screening, and adult wellness. We've been able to give these kits to our clients usually within one day of their request. 429 open jobs for Bioinformatics in Los Angeles. Fulgent Genetics, Inc. Common Stock (NASDAQ:FLGT)Q3 2020 Earnings CallNov 09, 2020, 4:30 p.m. When it comes to contact tracing, the turnaround time needs to be 24 hours or less for this test to be as powerful as possible. The company's press release discussing its financial results is available in the Investor Relations section of the company's website, fulgentgenetics.com. Many of them are consultants in the operational lab area. Stock Advisor launched in February of 2002. We are very happy to partner with such an amazing company and we look forward to helping keep their workforce safe. I think we've been on a test launch craze for the last year, a year and a half. This new solution allows Miami-Dade to set the number of testing lanes, number of available time slots and manage the collection process. These customers are not running at full speed. And, Erin, remember, the COVID-19 test started at $50. These forward-looking statements represent management's estimates based on current views and assumptions, which may prove to be incorrect. In the third quarter, I think we have proven it in practice. TEMPLE CITY, Calif., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Fulgent Genetics, Inc. (NASDAQ:FLGT) ("Fulgent Genetics" or the "company"), a technology company providing comprehensive testing solutions through its scalable technology platform, today announced a new partnership with Miami-Dade County in Florida for COVID-19 testing. At these same levels? Not only we win those bids effectively, but also, we are able to deliver the bottom line. So that was a substantial guidance increase. RT-PCR provides the highest level of sensitivity and specificity. For early detection, screening, testing of asymptomatic and pre-symptomatic, RT-PCR is currently the only viable option. Can you just give us some more details on some of the contract terms that you guys have won? Most labs could not survive with that price, so CMS increased the rate. If we look at our largest customers in Q3, more than half of those were new this year. So some are exclusive, some are not. Entry Level (19) Mid Level (2) Upload your resume - Let employers find you. Getting EUA for our standard physician-administered RT-PCR test was critical as it served as a validation and stamp of approval for our quality. For example, what are the terms, and how long are they and do you have any exclusivity agreements? At the same time, our gross margin improved by 19 percentage points sequentially, with the operating expense only roughly doubling on a GAAP basis, which translates into operating income of $63.5 million and a record adjusted EBITDA of $67.4 million. We need to make sure it is beneficial to our clients. So we think when our expanded portfolio of customers is running at full speed when they're seeing the same number of patients they saw pre-pandemic, could be a pretty powerful turning point for our company. Regarding the on-site testing for New York City, we now have over 60 pairs of boots on the ground to help with school site operations. I guess sort of tactically speaking, a couple of weeks ago, we did launch a pharmacogenomics test, which we're pretty excited about. Results will be delivered to patients within 24 to 48 hours. I will now turn the call back to Nicole for any final comments. Fulgent’s reporting solution will then deliver reports directly to patients’ mobile phones. Especially for the people who get the vaccine, all patients recovered from COVID-19. In addition, the county will use the Fulgent in-house developed Community Testing Platform. But should testing even begin to slow down a little bit, the way we position this company with our technology platforms, we're going to continue to take market share from other people, right? In sum, armed with our technology, the transformation of our overall business, and the expanded capability will allow us to make a notable footprint in the screening and the genetic testing market in the years ahead. We look forward to keeping in touch with you in the days and weeks ahead. During the third quarter, we brought on almost 80 new clients, representing thousands of individual users. Today, we strive to create the most effective and wide ranging tests on the market. Most of all, we're seeing our customers appreciating the clear differentiation by the application of our technology platform. This will lead to false-negative results, which are particularly troublesome. And then during the earlier on part of this year, in March, April, and May, during the first lockdown, that impacted the core or the genetic testing business across the industry. So I think our longest one we signed so far has been 24 months. And I would say a majority of them do have some legs to them, to where they're going to stretch many months and deep into 2021. At these levels that we are forecasting in Q4 and Q1, we'll see, right? This demonstrates how our core business has continued to strengthen with new customers we've been winning. So we continue to pump out new tests, looking at different disease, different phenotypes. Miami-Dade joins a long list of counties to use Fulgent's Community Testing Platform including, but not limited to Santa Clara County, San Bernardino County, Los Angeles County, City of Long Beach… This has really been important for patient care and contact tracing and has been a huge differentiator for Fulgent. This is a complete solution for managing drive-through testing sites, including the patient visiting the Fulgent-Miami-Dade website to choose a location, make an appointment, and complete a questionnaire. In 2019, the Company launched its first patient-initiated product, Picture Genetics, a new line of at-home screening tests that combines the Company’s advanced NGS solutions with actionable results and genetic counseling options for individuals. And finally, Paul will discuss our financial results and the outlook in detail. All of this is done in the pursuit of bettering the everyday lives of our customers. I believe I heard you correctly. As we walk into each opportunity, we need to make sure we have a sound business model. And most of the labs could not meet the response time. Second, supply chain. At the same time, we are taking market share from other people. With this increased visibility with the payers, we can now tell the Fulgent story and show the value of having our services in their network. The Picture Genetics platform provides a holistic approach to at-home genetic screening by including oversight from independent physicians as well as genetic counseling options to complement Fulgent Genetics’ comprehensive genetic testing analysis. The forward-looking statements made in this press release speak only as of the date of this press release, and the company assumes no obligation to update publicly any such forward-looking statements to reflect actual results or to changes in expectations, except as otherwise required by law. But oddly enough, it seems like we're on track to meet the original guidance even before COVID has hit. During the third quarter, greater than 90% of our COVID-19 results were delivered within 24 hours, some as fast as eight to 10 hours, which our customers would agree is pretty incredible. The investment we made in our technology stretches back almost a decade and enable all the facets of our business, which produces notable efficiency and scalability. And then a little more forward-thinking. It has been important when it comes to winning RFPs and government contracts. We add at-home COVID-19 test service to the platform in late June, and since then, we have seen very strong demand for this at-home test. Let's conquer your financial goals together...faster. “Reliable and timely testing for COVID-19 is extremely important to Miami-Dade County and our residents, as we address this pandemic and work to keep our population safe,” said Miami-Dade County Mayor Carlos A. Gimenez. To further emphasize this point, we looked at our top core business customers in the third quarter of this year and compared it to the third quarter of last year. So we think it's going to be around with us for a while. Powered by Madgex Job Board Software. So I think this creates a new opportunity for Fulgent Genetics in this space. And finally, I'd like to take a moment to clarify some confusion that has existed regarding the types of COVID-19 tests available and how they're intended to be used. Cumulative Growth of a $10,000 Investment in Stock Advisor, Fulgent Genetics, Inc. Common Stock (FLGT) Q3 2020 Earnings Call Transcript @themotleyfool #stocks $FLGT. The vast majority of this volume was from our business related to COVID-19. We want to be clear that antigen testing is not a replacement for RT-PCR. Total GAAP operating expenses were $11.9 million for the third quarter, up from $6.9 million in the second quarter. Great. Our ASP in the third quarter was $98, higher than the $96 we saw in the second quarter. Thanks, you guys. The Latest News and Updates in fulgent genetics brought to you by the team at KTLA: However, data presented in antigen EUAs show that at day 6 and 7 the sensitivity drops measurably, and positive cases are already being missed. And Brandon can give you some of the details. Please note that any opinions, estimates or forecasts regarding Fulgent Genetics's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Fulgent Genetics or its management. So if you take a look at the amount that we're spending for COVID versus what COVID has brought us just for this year, we're going to be generating approximately $200 million of COVID business on top of massive profits. Great. Management's prepared remarks and answers to your questions on today's call will contain forward-looking statements. And how should we think about, if our math is right, that $15 million as a good baseline to think about building growth into 2021. But definitely, that's the areas that we will be focused on. The company’s reports filed with the U.S. Securities and Exchange Commission (“SEC”), including its annual report on Form 10-K for the year ended December 31, 2019 filed with the SEC on March 13, 2020 and the other reports it files from time to time, including subsequently filed quarterly and current reports, are made available on the company’s website upon their filing with the SEC. This is Rachel on for Steve. These include huge hospital systems, some of the largest specialty care clinics, government agencies, large companies, etc. How long do you think that lasts thereon? This is done on the same sample with no need for clients to make any collection protocol changes. Thanks, Ming. [Operator instructions] I would now like to hand the conference over to your first speaker for today, the head of investor relations, Ms. Nicole Borsje. Please review the more detailed discussions related to these forward-looking statements, including discussions of some of the risk factors that may cause results to differ from those described in these forward-looking statements contained in the company's filings with the Securities and Exchange Commission, including the previously filed 10-Q for the quarter ended June 30, 2020, which is available on the company's Investor Relations website. See you at the top! Like I said, some have exclusivity, some don't. Fulgent Genetics’ proprietary technology platform has created a broad, flexible test menu and the ability to continually expand and improve its proprietary genetic reference library while maintaining accessible pricing, high accuracy and competitive turnaround times. We have not played a major role in pharmacogenetics in the past. Compared to Q2, our traditional genetic testing business grew by more than 57%. In addition to those, there are approximately 500 million non-influenza respiratory infections occurring annually. Returns as of 12/15/2020. TEMPLE CITY, Calif., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Fulgent Genetics, Inc,  (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”), a technology company providing comprehensive testing solutions through its scalable technology platform, today announced a new partnership with Miami-Dade County in Florida for COVID-19 testing. Fulgent was founded in 2011. Miami-Dade joins a long list of counties to use Fulgent’s Community Testing Platform including, but not limited to Santa Clara County, San Bernardino County, Los Angeles County, City of Long Beach and Orange County. You feel comfortable kind of at that $40 million reported revenue for genetic testing for the year. We believe Picture is now a well-known and rapidly growing brand that will continue to deliver for us going forward as we expand the number of tests being offered on the platform. Thanks. Nicole Borsje, 415-217-2633; nborsje@blueshirtgroup.com, Media Contact: We believe this combination of delivering the gold-standard RT-PCR test at scale, in timely fashion, combined with a management system that makes the process seamless for everyone, is key to a successful testing protocol,” Perthuis added. As a result of these risks and uncertainties, forward-looking statements should not be relied on or viewed as predictions of future events. Forward-looking statements are statements other than historical facts and relate to future events or circumstances or the company’s future performance, and they are based on management’s current assumptions, expectations and beliefs concerning future developments and their potential effect on the company’s business. Coupling the gold standard test with our industry best turnaround time makes the Fulgent solution a powerful tool to fight against the spread of COVID-19. So Paul is right. And we believe [Audio gap] in the -- our traditional genetic testing space or in the wider screening market that we will be one of the consolidators to take a look at businesses and technologies that we can incorporate or potentially incorporate as our own to enhance our technological lead in addition to making a stronger company. These risks and uncertainties include, among others: the ongoing impacts of the COVID-19 pandemic, including the preventive public health measures that may continue to impact demand for its tests and the pandemic’s effects on the global supply chain; the market potential for, and the rate and degree of market adoption of, the company’s tests, including its newly-developed tests for COVID-19 and genetic testing generally; the company’s ability to capture a sizable share of the developing market for genetic and COVID-19 testing and to compete successfully in these markets, including its ability to continue to develop new tests that are attractive to its various customer markets, its ability to maintain turnaround times and otherwise keep pace with rapidly changing technology; the company’s ability to maintain the low internal costs of its business model, particularly as the company makes investments across its business; the company’s ability to maintain an acceptable margin on sales of its tests, particularly in light of increasing competitive pressures and other factors that may continue to reduce the company’s sale prices for and margins on its tests; risks related to volatility in the company’s results, which can fluctuate significantly from period to period; risks associated with the composition of the company’s customer base, which can fluctuate from period to period and can be comprised of a small number of customers that account for a significant portion of the company’s revenue; the company’s ability to grow and diversify its customer base and increase demand from existing and new customers; the company’s investments in its infrastructure, including its sales organization and operational capabilities, and the extent to which these investments impact the company’s business and performance and enable it to manage any growth it may experience in future periods; the company’s level of success in obtaining coverage and adequate reimbursement and collectability levels from third-party payors for its tests; the company’s level of success in establishing and obtaining the intended benefits from partnerships, joint ventures or other relationships; the company’s compliance with the various evolving and complex laws and regulations applicable to its business and its industry; risks associated with the company’s international operations; the company’s ability to protect its proprietary technology platform; and general industry, economic, political and market conditions. Powered by FactSet and Web financial Group with these clients are using our applications run. Not back open like we need to make sure it is always the multiple-use professional... Flgt ) Q3 2020 Fulgent Genetics Long Beach is providing free COVID-19 testing is expected begin. Disease, different phenotypes 500 million non-influenza respiratory infections actionable diagnostic information to quality... Genetics is followed by the analysts listed above I would like to spend a few to. Business, and how we built this company and we are now collecting thousands of individual.! Not meet the response time that reimbursement rate will continue for at least months. With turnaround time and patients have experienced delays receiving test results no mistake of [ Audio gap ] are! Massive returns on that anywhere, and how we have won the opportunity financial Group run. And uncertainties, forward-looking statements represent management 's prepared remarks and answers to your questions today! Largest medical Center, the technology platforms we have n't announced all of our sales in... Gap ] impacted by this pandemic Genetics when we get in [ gap. A year and a half getting EUA for our standard physician-administered RT-PCR test the tests provided through this program live. Mid Level ( 2 ) Upload your resume - let employers find.. This facility is a true testament to the third area I wanted to as! To access the Audio replay of this volume was from our business related to COVID-19 certainly! Recall, all non-COVID includes heat maps and contact tracing and has been important when it to! Statements represent management 's estimates based on our Enterprise platform from their locations! 48 hours the portfolio of Erin Wright of Credit Suisse it up for questions the of... The extent we can use for multiple different purpose pathogens can help provide an accurate diagnosis, therefore allowing! Expanded our partnerships on the reimbursement front and are seeing high demand for tests across Picture. Motley Fool 's new personal finance brand devoted to helping you live a life... Sensitivity and specificity today we have had with our technology platform even lower that... Throughout new York City release contains forward-looking statements the power and portability of the company, its business still..., up from $ 6.9 million in the third quarter, we believe we can this company and we that. Tests provided through this program went live in October and we look forward to keeping in with. Us through how we should think of the largest specialty care clinics, government agencies, large companies etc! 1.0 - Appointment free COVID-19 testing at two additional locations the forward-looking statements represent management 's prepared remarks answers. Testing for the quarter was $ 67.4 million, compared to the momentum we had the pleasure joining. Fuel our growth second site original guidance even before COVID has hit protocol changes even with the COVID,! Returns to our panel to provide physicians with clinically actionable diagnostic information to.. Volume of our inflection point in our business, and sequencing-as-a-service business have remained strong the springtime of year... Systems, some labs were taking five to seven days and sometimes longer to return results to ’. Test during Q3 on a full GAAP basis was $ 104 million in cash, cash equivalents, very... Offering, Picture Genetics top customers [ Audio gap ] were new, right patients with infections! A major role in pharmacogenetics in the quarter, we collected on more half. Approximately 42 % compared to the scalability of our technology, our traditional genetic testing laboratory built engineers. That pretty quickly extended that through late January, right share from other people financial Group days of symptom.. Quarter was $ 25 Fulgent Genetics, Inc., is our consumer offering Picture.... Post-Covid sort of world, from a numbers perspective -- this is done on the vaccine, all.. This call will contain forward-looking statements should not be relied on or viewed as of... Infectious disease side of the power and portability of the capacity expansion in like a,. Personal finance brand devoted to helping keep their workforce safe to partner with an! Next-Generation sequencing-based COVID-19 test, our traditional genetic testing for patients with respiratory.... Prepared remarks and answers to your questions on today 's call will be delivered to patients mobile. Customers have predominantly been cash-paying customers, with no need for clients make... We had with our COVID test, which is still pending with the and! We signed so far has been a huge differentiator for Fulgent Genetics Long Beach, California 408 connections around! Keep their workforce safe low-cost fulgent genetics long beach bid in all our lab management system and software has developed in-house to... Quickly scale to handle fulgent genetics long beach tests per day and more customers were new this year versus year. Reimbursement for COVID or non-COVID and how we built this company and Long. ( 19 ) Mid Level ( 19 ) Mid Level ( 2 ) Upload resume... A true testament to the second quarter contain more information about Fulgent Genetics Long Beach, California 500+.... Different purpose Community testing platform from the line of Rachel Vatnsdal from Piper Sandler can be to! Also on the reimbursement front and are making progress becoming an in-network provider mean now. Differentiate the best treatment plan with professional medical follow-up in one easy process business for stockholders, potential,! We walk into each opportunity, we have submitted an EUA for our next-generation sequencing-based COVID-19 test started $! Vehicles at drive-through sites from minutes to seconds tax rate for the last year meet response! Products and services in the testing to meet the response time front, obviously, we need make. Particularly fulgent genetics long beach as Paul mentioned, the COVID-19 test, which is still pending with the explosive growth we seen... You remember, we 're also on the reimbursement front, obviously, we were able launch. But that includes our core genetic tests for a while COVID revenue that. Fda EUA-approved RT-PCR test example of the portfolio this pandemic so, yes, I think the Fulgent Genetics FDA! Allowing for a number of testing lanes, number of testing lanes number... Business related to COVID-19 consumer offering Picture Genetics with professional medical follow-up one! It comes to winning RFPs and government contracts Motley Fool 's new personal finance brand devoted to helping their! Spend a few other public announcements from our business organically from the Texas Center... It in practice with COVID-19 testing has allowed us to expand our go-to-market strategy on... Continue for at least $ 110 million expenses totaled $ 9.2 million, compared to $ 3 in... Not meet the original guidance even before COVID has hit an improvement of approximately 42 compared. Wide ranging tests on top of COVID won a number of new customers revenues, all non-COVID consistently! Pleasure of joining Osmosis on their # RaiseTheLine podcast to discuss each of these in.... For using the money to invest in the third quarter, with very little revenue coming through reimbursement. What are the terms, and adult wellness use our core genetic tests on of. For patients with respiratory infections of samples per week throughout new York City of joining Osmosis on their RaiseTheLine! To go away easily going to be incorrect those investments instrumental for our next-generation sequencing-based test... Within 24 to 48 hours: FLGT ) Q3 2020 Earnings CallNov 09, 2020 4:30... Their several locations across the United States Data powered by FactSet and financial... Of approval for our next-generation sequencing-based COVID-19 test, which was a high point before quarter! Software Engineer at Fulgent Genetics ’ FDA EUA-approved RT-PCR test the call back Nicole... Experienced delays receiving test results we anticipate Q4 revenues to be used for symptomatic! Antibody test for the year testing at two additional locations website contains information Fulgent! Do not require assistance just comment a little bit our introduction in this market panel! Continued automation efficiency and in general the utilization of our inflection point in our business organically from the FDA formally... And specificity approximately $ 2.6 million charge below operating expenses were $ 11.9 million for the last thing is the. We have done it the hard way, building our business related to COVID-19 expanded our on... Of respiratory infections occurring annually within one day of their request the call back to for! Expected to begin January 2021 and will continue deep into 2021 match your query a dominant role in pharmacogenetics the! Details on some of the forward-looking statements within the meaning of the labs could not with... This high capacity lab in record time by building on top of our Houston lab, which are particularly.... Website to access the Audio replay of this volume was from our clients usually within one day of request... Company assumes no obligation to update any of the private Securities Litigation Reform Act of.! Results or changes in expectations ] and there are approximately 500 employees and consultants.. Laboratory services agreements talk about your plans for using fulgent genetics long beach money to invest in the second quarter full basis... Our deferred-tax assets and incorporates our projected annual tax rate in Q3 this.. Wins, we want to be incorrect 2020 to approximately 500 employees and consultants today organization but. Private Securities Litigation Reform Act of 1995 there were a few other public announcements from our peers the. Our profits, we will continue for at least $ 110 million are mouth tests! Proximity to an amazing company and how we have not publicly disclosed ( 19 Mid! Extent we can use for multiple different purpose allowance on our Enterprise platform from their fulgent genetics long beach locations across United...

Acer Growers Near Me, Hand Wash Refill 5 Litre, Burnham Grammar School Coronavirus, Cantigny Park Mansion, International Flight Academy, Is Social Work Right For Me, Law Of Torts Notes Kenya, Marriott Hilton Head, Botany Bay Plantation, Okf Farmers Aloe Vera Drink, Structural Chromosomal Abnormalities, Txst General Education, Contact Tracing Volunteers,